What is the dosage of Zolbetuximab-Vyloy?

Zolbetuximab (Zolbetuximab), trade name Vyloy, is an innovative targeted antibody drug specifically used to treat adult patients with Claudin 18.2-positive gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma. As a drug used in combination with chemotherapy, zotuximab has achieved significant clinical results in terms of therapeutic efficacy. But to ensure maximum efficacy and safety, correct usage and dosage are crucial.

The use of zotuximab first requires patients to meet certain indications, that is, the patient must have HER2-negative gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, and the tumor cells must express Claudin 18.2 (CLDN18.2)-positive. This is usually confirmed by immunohistochemistry (IHC) testing. For eligible patients, zotuximab is often combined with fluoropyrimidine- and platinum-containing chemotherapy drugs, which can increase the effectiveness of the treatment.

In terms of usage, the initial therapeutic dose of zotuximab is 800 mg per square meter of body surface area administered by intravenous infusion. This dosage needs to be adjusted under the guidance of a doctor, as individual differences may affect the effectiveness and safety of the drug. Subsequently, during the maintenance phase, the dose of zotuximab is adjusted, usually 600 mg intravenously every 3 weeks or 400 mg every 2 weeks until disease progression or intolerable side effects occur.

Before using zotuximab, doctors usually advise patients to take antiemetics before injecting the drug to reduce possible nausea and vomiting reactions, especially for first-time patients. In addition, if the patient experiences adverse reactions during treatment, such as severe nausea, vomiting, or allergic reactions, the doctor may adjust the dose or suspend treatment based on the patient's specific condition.

It is worth noting that the dose of zotuximab is not recommended to be reduced, especially during use. Doctors will monitor the effects and side effects of the drug based on the patient's specific condition. Patients need to closely cooperate with the doctor's treatment plan and undergo regular examinations to ensure the safety and effectiveness of the treatment.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7695a21-abb6-47ac-93f8-0ece5a9c4409